PCN Insights, News, Videos, and More

Caffeine use combined with extended-release viloxazine appeared to increase the likelihood of insomnia but no other caffeine-related adverse events in adults with ADHD, according to a poster presentation on September 18th at Psych Congress in...

Cariprazine could be effective in treating patients with major depressive disorder and inadequate response to antidepressant treatment.

CEO Alliance for Mental Health members presented a message of unification, urgency, and equity.

In a phase 3 trial, lumateperone significantly improved depression in patients with bipolar I or II disorder.

The US Food and Drug Administration has provided Magnus Medical Inc. 510(k) clearance for the SAINT Neuromodulation System for the treatment of MDD in adults who have not achieved adequate improvement from prior antidepressant medications in...

MAPS is collaborating with Sunstone Therapies to conduct a clinical trial testing the safety and tolerability of MDMA-assisted therapy for patients with treatment-resistant post-traumatic stress disorder.

Adjunctive brexpiprazole was associated with significant gains in patient life engagement in adults with major depressive disorder (MDD) and inadequate response to antidepressant treatment, according to a poster presented at Psych Congress.

An interim analysis of a phase 3, open-label, year-long study evaluating episodic treatment with zuranolone for major depressive disorder found the majority of patients at study exit had minimal or mild depressive symptoms, including those...